2006
Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program
Govindan R, Natale R, Wade J, Herbst R, Krebs A, Reiling R, Hensing T, Wozniak A, Belani CP, Kelly K, Ochs J. Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program. Lung Cancer 2006, 53: 331-337. PMID: 16797779, DOI: 10.1016/j.lungcan.2006.04.013.Peer-Reviewed Original ResearchConceptsAdvanced non-small cell lung cancerNon-small cell lung cancerExpanded Access ProgramCell lung cancerLung cancerRecurrent advanced non-small cell lung cancerEpidermal growth factor receptor tyrosine kinase inhibitor gefitinibNumerous clinical guidelinesSafety of gefitinibBest supportive careCommon adverse eventsPartial response ratePoor performance statusRetrospective chart reviewMajority of patientsTyrosine kinase inhibitor gefitinibFavorable toxicity profileAccess programKinase inhibitor gefitinibPrevious chemotherapyStable diseaseSubsequent chemotherapyChemonaive patientsAdverse eventsChart review
2004
Pemetrexed in advanced NSCLC: a review of the clinical data.
Zinner RG, Fossella FV, Herbst RS. Pemetrexed in advanced NSCLC: a review of the clinical data. Oncology 2004, 18: 54-62. PMID: 15339061.Peer-Reviewed Original ResearchConceptsAdvanced NSCLCConcurrent chest radiationPhase II studySecond-line therapyPhase III trialsCell lung cancerFavorable toxicity profileTreatment of mesotheliomaChest radiationII studyIII trialsSystemic dosesThoracic malignanciesFrontline settingLung cancerClinical dataToxicity profilePlatinum agentsSide effectsUS FoodDrug AdministrationPhase IPemetrexedNSCLCNovel mechanismPemetrexed in the Treatment of Advanced Non–Small-Cell Lung Cancer: A Review of the Clinical Data
Zinner RG, Herbst RS. Pemetrexed in the Treatment of Advanced Non–Small-Cell Lung Cancer: A Review of the Clinical Data. Clinical Lung Cancer 2004, 5: s67-s74. PMID: 15117428, DOI: 10.3816/clc.2004.s.006.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerSecond-line activityPhase III trialsIII trialsLung cancerAdvanced non-small cell lung cancerPhase II studyFirst-line therapyCell lung cancerFavorable toxicity profileChest radiationII studyThoracic malignanciesClinical dataSignificant efficacyToxicity profileSide effectsUseful agentFDA approvalPemetrexedPhase ICisplatinTrialsFurther studiesMesothelioma